Acorda Therapeutics Inc. (ACOR)’s Financial Results Comparing With Cleveland BioLabs Inc. (NASDAQ:CBLI)

Acorda Therapeutics Inc. (NASDAQ:ACOR) and Cleveland BioLabs Inc. (NASDAQ:CBLI) are two firms in the Biotechnology that compete against each other. Below is a comparison of their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acorda Therapeutics Inc. 11 0.46 N/A -0.43 0.00
Cleveland BioLabs Inc. 2 14.37 N/A -0.29 0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 represents Acorda Therapeutics Inc. (NASDAQ:ACOR) and Cleveland BioLabs Inc. (NASDAQ:CBLI)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Acorda Therapeutics Inc. 0.00% -1% -0.4%
Cleveland BioLabs Inc. 0.00% 282.5% -61.9%

Volatility and Risk

Acorda Therapeutics Inc. has a 1.1 beta, while its volatility is 10.00%, thus making it more volatile than Standard & Poor’s 500. In other hand, Cleveland BioLabs Inc. has beta of 0.64 which is 36.00% less volatile than Standard & Poor’s 500.

Liquidity

Acorda Therapeutics Inc.’s Current Ratio and Quick Ratio are 4.3 and 4 respectively. The Current Ratio and Quick Ratio of its competitor Cleveland BioLabs Inc. are 3.7 and 3.7 respectively. Acorda Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to Cleveland BioLabs Inc.

Analyst Recommendations

Acorda Therapeutics Inc. and Cleveland BioLabs Inc. Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Acorda Therapeutics Inc. 0 3 1 2.25
Cleveland BioLabs Inc. 0 0 0 0.00

Acorda Therapeutics Inc. has a consensus target price of $15.67, and a 436.64% upside potential.

Institutional and Insider Ownership

Institutional investors held 0% of Acorda Therapeutics Inc. shares and 5.2% of Cleveland BioLabs Inc. shares. Insiders held roughly 1.5% of Acorda Therapeutics Inc.’s shares. Insiders Comparatively, held 58.14% of Cleveland BioLabs Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Acorda Therapeutics Inc. 1.61% -9.88% -31.04% -57.92% -71.54% -55.52%
Cleveland BioLabs Inc. 6.38% -1.87% 9.03% 11.35% -36.08% 55.45%

For the past year Acorda Therapeutics Inc. has -55.52% weaker performance while Cleveland BioLabs Inc. has 55.45% stronger performance.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that has completed a Phase III clinical trial for the treatment of OFF periods in ParkinsonÂ’s disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; Tozadenant that is in Phase III clinical trial for reduction of OFF time in ParkinsonÂ’s disease; SYN120, which is in Phase II clinical trial to treat ParkinsonÂ’s disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; Cimaglermin alfa that has completed a Phase I clinical trial in heart failure patients; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King's College London; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and WomenÂ’s Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and the Russian Federation. The companyÂ’s advanced product candidate is entolimod, a Toll-like receptor 5 (TLR5) agonist that is used to prevent death from acute radiation syndrome, and as an oncology drug. It is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. In addition, the company develops CBL0137, a small molecule with a multi-targeted mechanism of action used for the treatment of various types of cancer. Cleveland BioLabs, Inc. has strategic partnerships with The Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.